Response to inhaled ceftazidime in patients with non‐cystic fibrosis bronchiectasis and chronic bronchial infection unrelated to Pseudomonas aeruginosa

INTRODUCTION: Inhaled antibiotics reduce the frequency of exacerbations. The objective was to assess the efficacy of inhaled ceftazidime in patients with non‐cystic fibrosis bronchiectasis (NCFB) and concomitant chronic bronchial infection (CBI) caused by potentially pathogenic microorganisms (PPM)...

Descripción completa

Detalles Bibliográficos
Autores principales: Riveiro, Vanessa, Casal, Ana, Álvarez‐Dobaño, José M., Lourido, Tamara, Suárez‐Artime, Pedro, Rodríguez‐García, Carlota, Ferreiro, Lucía, Toubes, María E., Valdés, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629990/
https://www.ncbi.nlm.nih.gov/pubmed/36017771
http://dx.doi.org/10.1111/crj.13534
Descripción
Sumario:INTRODUCTION: Inhaled antibiotics reduce the frequency of exacerbations. The objective was to assess the efficacy of inhaled ceftazidime in patients with non‐cystic fibrosis bronchiectasis (NCFB) and concomitant chronic bronchial infection (CBI) caused by potentially pathogenic microorganisms (PPM) other than Pseudomonas aeruginosa (PA). MATERIAL AND METHOD: Quasi‐experimental study in 21 patients with exacerbations who developed CBI by a PPM other than PA. RESULTS: Bacterial infection was resolved in 85.7% patients. Rehospitalizations, length of hospital stay, moderate exacerbations and blood levels of CRP decreased significantly. In addition, SGRQ questionnaire also decreased more than 4 points in 57.1% of the patients. CONCLUSION: The results suggest that inhaled ceftazidime in NCFB unrelated to PA is a plausible alternative to the standard therapies used in clinical practice.

Ejemplares similares